Loading data for IRON — first visit, this takes a few seconds.

알림

Disc Medicine Inc. (IRON)

NasdaqGM: IRON · 실시간 가격 · USD

79.81

+0.97 (1.23%)

종가 기준: Aug 21, 2026, 8:00 PM

79.81

+0.00%

애프터마켓: 7:30 PM

주가와 핵심 숫자, 최신 뉴스를 한 곳에 모았습니다.

1.23% (1D)

데이터 없음

매수호가	56.05
시가총액	3.06B
매출 (ttm)	n/a
순이익 (ttm)	-245.89M
	2.06
	-6.59
	n/a
	-10.99
P/B (ttm)	4.75
P/S (ttm)	n/a
실적 발표일	Nov 5, 2026

매도호가	77.67
거래량	365,365
평균 거래량 (20일)	519,708
시가	79.50
전일 종가	78.84
일중 범위	78.10 - 80.00
52주 범위	40.00 - 99.50
애널리스트	n/a
목표주가	n/a
배당	n/a
배당락일	n/a

IRON 소개

Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood c...

[더 보기]

산업 Biotechnology

섹터 Healthcare

IPO 일자 Aug 12, 2020

직원 수 165

상장 거래소 NasdaqGM

티커 IRON

웹사이트 https://www.discmedicine.com

전체 기업 정보

재무 실적

2025년 Disc Medicine의 매출은 0로, 전년 0 대비 undefined% 증가했습니다. 순이익은 -212.18M로, 94.03% 증가했습니다.

재무제표

어닝 서프라이즈

Disc Medicine가 Jul 30, 2026에 분기 실적을 발표했습니다:

매출 $0 예상치 하회 $0, 및 NaN% 전년 대비 성장.
EPS -1.54 예상치 상회 0.23, 및 2.53% 전년 대비 성장.

다음 실적 발표

Disc Medicine Inc.의 실적 발표 예정일은 Nov 5, 2026, 장 시작 전입니다.
애널리스트 예상 매출은 ... 업그레이드

뉴스

6일 전 · MT Newswires

Contineum, Disc Medicine, Recursion Advance Pipelines Ahead of Catalysts, Morgan Stanley Says

Contineum Therapeutics (CTNM), Disc Medicine (IRON), and Recursion Pharmaceuticals (RXRX) are making

2개월 전 · Simply Wall St.

How Investors May Respond To Disc Medicine (IRON) Expanding Pre-Approval Access To Bitopertin For Porphyria Patients

Disc Medicine has launched a U.S. expanded access program for its investigational drug bitopertin, allowing eligible erythropoietic protoporphyria and X-linked protoporphyria patients aged 12 and abov...

2개월 전 · MarketBeat

Disc Medicine Eyes Mid-2026 Bitopertin Approval as EPP Trial Demand Surges

Disc Medicine (NASDAQ:IRON) Chief Executive Officer John Quisel said patient demand for the company’s bitopertin program in erythropoietic protoporphyria, or EPP, remains strong after the company enro...

3개월 전 · Simply Wall St.

A Look At Disc Medicine (IRON) Valuation After Legal Probes And FDA Complete Response Letter

Disc Medicine (IRON) stock has been in focus after law firms began investigating potential securities claims linked to allegedly misleading business information following an FDA Complete Response Lett...

4개월 전 · Motley Fool

Disc Medicine Insider Sells $380K in Stock Amid 70% One-Year Surge

Disc Medicine advances therapies for serious blood disorders; a key insider recently trimmed their stake amid strong one-year share gains.

2 페이지 중 1

Disc Medicine Inc. (IRON)